الأربعاء 13 ربيع الأول 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): A Randomized Controlled Clinical Trial | Sunnybrook Health Sience Center / KAIMRC | Ongoing | All SFDA already registered Antibiotics | 4 | CT 15/022 | King Abdulaziz Medical City NG (Riyadh) |
| ChaRactErization of patients following aCute venous thrOmboembolism (VTE) and assessment of safety and effectiveness of dabigatran etexilate (DE) in the tReatment and secondarY prevention of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in comparison to vitamin K antagonist (VKA) in routine clinical practice - RE-COVERY DVT/PE | Boehringer Ingelheim | Ongoing | Dabigatran etexilate | 4 | 1160.188 | King Salman Bin AbdulAziz Hospital |
| Forxiga (dapagliflozin) Post Authorization Safety Study | AstraZeneca | Ongoing | Forxiga | 4 | D1690R0003 | King Khalid University Hospital (Riyadh), Taibah University College of Medicine, Dr. Sulaiman Al-Habib Medical Group (Riyadh), Specialized Medical Center (Riyadh), International Medical Center (Jeddah), Dallah Hospital (Riyadh), King Abdulaziz University Hospital (Jeddah) |
| A Multicenter, prospective, non-interventional study to assess Adherence to treatment for patIeNts with Relapsing Multiple Sclerosis (RMS) who are prescribed subcutaneous (sc) interferon beta-1a | Merck Serono | Ongoing | Interferon Beta-1 a (Rebif) | 4 | MS200136_0 | King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Faisal Specialist Hospital and Research Center (Jeddah) |
| "CAIN457A3404-REALIAA non-interventional, prospective 12-months study to characterize the REAL-life effectiveness and treatment patterns of SecukInumab and current standard of care inpatient with chronic plaque psoriAsis eligible for systemic treatment in the Asia-Pacific and Middle East regions" | Novartis | Ongoing | Cosyntex | 4 | IN457A3404 | King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| Does the Addition of Proton Pump Inhibitors to Continuous Enteral Feeding Provide Added Protection Against Upper GI Bleeding in Acutely Ill Patients | KAIMRC | Ongoing | Esmoprozol | 4 | RC15/079 | King Abdulaziz Medical City NG (Riyadh) |
| Real World retrospective study of effectiveness and safety of Gilenya (FINgOlimod) in relapsing remitting Multiple Sclerosis in the Middle East and North Africa (FINOMENA) | Novartis | Ongoing | Fingolimod | 4 | TY720DAE01 | King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah), King Abdulaziz Hospital Oncology Center, King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), Hira Hospital (Makkah), King Fahad Specialist Hospital (Dammam), Dr. Erfan & Bagedo General Hospital (Jeddah) |
| A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis | Novartis | Ongoing | ofatumumab | 3 | COMB157G2301 | King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease | Abbvie Biopharmaceuticals GmbH / KSU Liver Disease Research Center | Ongoing | ombitasvir \ paritaprevir \ ritonavir | 3 | Version 1.3.1 | King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah) |
| "Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation" | Novartis | Ongoing | deferasirox | 2 | CICL670FIC05 | King Abdulaziz University Hospital (Jeddah), Hereditary Blood Disease Center (al ahsa), King Abdulaziz Medical City NG (Riyadh) |
تاريخ آخر تحديث: 10/09/2026 بتمام الساعة 10:01 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.